⚠ R&D's Rising Cost and Falling OddsModerate threat

The R&D engine that powers Lilly is also an enormous, uncertain money-consuming machine, and the economics of drug discovery have grown harder over time. Bringing a single new drug to market now costs billions of dollars and takes a decade or more, the failure rate is punishing, and the industry has long grappled with declining research productivity — more money spent for each new drug approved. A company whose future depends on out-inventing its patent cliffs is dependent on a process that is expensive, slow, and statistically unforgiving.

The danger is that Lilly must spend ever-larger sums to sustain its innovation, with no guarantee the output keeps pace. Its research budget runs to many billions a year, and that spending is a bet against long odds; a stretch of poor pipeline productivity — expensive failures, thin output of new blockbusters — would pressure both earnings and the growth story while the patent clock keeps ticking on existing drugs.

Lilly's recent research productivity has been exceptional, its pipeline unusually fertile, and its scale lets it fund R&D few rivals can match — real strengths that push against the industry's grim averages. But an owner should recognize that drug discovery is a costly lottery with worsening odds, that even the best companies endure dry spells, that Lilly's valuation assumes continued high productivity from a process that resists such assumptions, and that the R&D engine — however impressive its 25-plus Phase 3 slate looks lately¹ — is a source of ongoing cost and uncertainty as much as of future drugs.